Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Series A Brings CeNeRx $18.5M For Depression, Anxiety Drugs

Nov. 30, 2005

By Jennifer Boggs

Actelion: Pursuing Bosentan In Pulmonary Fibrosis Despite Miss

Nov. 30, 2005

By Jennifer Boggs

ABI In $4B Merger With APP To Create Abraxis BioScience

Nov. 29, 2005

By Jennifer Boggs

American BioScience Inc. and its majority-owned subsidiary, American Pharmaceutical Partners Inc., are combining to create a new company, Abraxis BioScience. (BioWorld Today)

ABI In $4B Merger With APP To Create Abraxis BioScience

Nov. 29, 2005

By Jennifer Boggs

American BioScience Inc. and its majority-owned subsidiary, American Pharmaceutical Partners Inc., are combining to create a new company, Abraxis BioScience. (BioWorld Today)

Required New Trial Of Vasovist Drops EPIX's Stock 14 Percent

Nov. 28, 2005

By Jennifer Boggs

Required New Trial Of Vasovist Drops EPIX's Stock 14 Percent

Nov. 28, 2005

By Jennifer Boggs

Nurel, Diamyd Combine GAD Technologies Through Merger

Nov. 23, 2005

By Jennifer Boggs

Nurel, Diamyd Combine GAD Technologies Through Merger

Nov. 23, 2005

By Jennifer Boggs

Solexa Raises $65M, Readies Sequencing System Launch

Nov. 22, 2005

By Jennifer Boggs

Solexa Raises $65M, Readies Sequencing System Launch

Nov. 22, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...